Short answer
Cryoport, Inc. (CYRX) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $50M (up 13.5% year over year) with net income of −$11M.
Q3 2026 key financials · XBRL
- Revenue
- $50M
- +13.5% YoY · +2.6% QoQ
- Net income
- −$11M
- −233.5% YoY · −31.5% QoQ
- Operating margin
- -17.5%
- Gross margin
- 47.5%
- EPS (diluted)
- −$0.26
- −160.0% YoY · −30.0% QoQ
Source: XBRL data from the Cryoport, Inc. (CYRX) Q3 2026 10-Q on SEC EDGAR. USD.
Cryoport, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $50.2M, up 13.5% YoY from $44.2M
- Gross margin 47.5% vs 48.2% YoY, Life Sciences Products margin 43.6% vs 46.4%
- Best segment: Life Sciences Services revenue $28.6M, up 17.8%; BioStorage/BioServices up 25.1%
- Operating cash flow $10.1M, versus $(9.5)M YoY; capital expenditures and equipment purchases $24.3M
- Near-term outlook: operating losses expected amid expansion and technology investment; $186.2M notes repayment due December 2026
Risk Factors
- No material changes to risk factors from the 2025 Annual Report
- Carried-forward risk: unidentified or currently immaterial factors could adversely affect operations
- Business risk: existing annual-report risks could materially impair financial condition and results
- Regulatory risk: annual-report risks remain applicable, with no new quarterly developments disclosed
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Cryoport, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.